A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
Public ClinicalTrials.gov record NCT01321554. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).
Study identification
- NCT ID
- NCT01321554
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 392 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 16, 2011
- Primary completion
- Nov 14, 2013
- Completion
- Mar 18, 2019
- Last update posted
- Jun 21, 2023
2011 – 2019
United States locations
- U.S. sites
- 38
- U.S. states
- 23
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Facility 1 | Little Rock | Arkansas | — | — |
| Facility 1 | La Jolla | California | — | — |
| Facility 1 | Los Gatos | California | — | — |
| Facility 1 | Mission Viejo | California | — | — |
| Facility 1 | Orange | California | — | — |
| Facility 2 | Orange | California | — | — |
| Facility 1 | Sacramento | California | — | — |
| Facility 1 | Torrance | California | — | — |
| Facility 1 | Aurora | Colorado | — | — |
| Facility 1 | Washington D.C. | District of Columbia | — | — |
| Facility 1 | Orlando | Florida | — | — |
| Facility 1 | Weston | Florida | — | — |
| Facility 1 | Chicago | Illinois | — | — |
| Facility 2 | Chicago | Illinois | — | — |
| Facility 1 | Indianapolis | Indiana | — | — |
| Facility 1 | Lexington | Kentucky | — | — |
| Facility 1 | Baltimore | Maryland | — | — |
| Facility 1 | Boston | Michigan | — | — |
| Facility 2 | Boston | Michigan | — | — |
| Facility 1 | Detroit | Michigan | — | — |
| Facility 1 | Lansing | Michigan | — | — |
| Facility 1 | Minneapolis | Minnesota | — | — |
| Facility 1 | Columbia | Missouri | — | — |
| Facility 1 | Omaha | Nebraska | — | — |
| Facility 1 | Lebanon | New Hampshire | — | — |
| Facility 1 | Morristown | New Jersey | — | — |
| Facility 1 | Neptune City | New Jersey | — | — |
| Facility 1 | New York | New York | — | — |
| Facility 2 | New York | New York | — | — |
| Facility 1 | The Bronx | New York | — | — |
| Facility 1 | Columbus | Ohio | — | — |
| Facility 1 | Portland | Oregon | — | — |
| Facility 1 | Philadelphia | Pennsylvania | — | — |
| Facility 2 | Philadelphia | Pennsylvania | — | — |
| Facility 1 | Houston | Texas | — | — |
| Facility 1 | Seattle | Washington | — | — |
| Facility 1 | Morgantown | West Virginia | — | — |
| Facility 1 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 117 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01321554, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01321554 live on ClinicalTrials.gov.